Proinflammatory potential of cytomegalovirus infection. Specific inhibition of cytomegalovirus immediate-early expression in combination with antioxidants as a novel treatment strategy?

Intervirology

Volumn 42, Issue 5-6, 1999, Pages 419-424

  Cinatl Jr , Jindrich ^a   Vogel, J U ^a   Kotchetkov, R ^a   Scholz, M ^a   Doerr, H W ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Antisense oligonucleotides; Antiviral drugs; Chemoattractants; Human cytomegaloviruses; Immunopathology

Indexed keywords

ANTIOXIDANT; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HYDROGEN PEROXIDE; IMMEDIATE EARLY PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; VIRUS ANTIGEN;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; FIBROBLAST; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PREPUCE; PRIORITY JOURNAL; VIRUS REPLICATION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0343550337     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053980     Document Type: Conference Paper

References (40)

1. Grundy JE: Current antiviral therapy fails to prevent the pro-inflammatory effects of cytomegalovirus infection, whilst rendering infected cells relatively resistant to immune attack; in Scholz M, Rabenau HF, Doerr HW, Cinatl J Jr (eds): CMV-related immunopathology. Monogr Virol, Basel, Karger, 1998, vol 21, pp 67-89.
2. Scholz M, Vogel J-U, Blaheta R, Cinatl J Jr: Cytomegalovirus, oxidative stress and inflammation as interdependent pathomechanisms: Need for novel therapeutic strategies? in Scholz M, Rabenau HF, Doerr HW, Cinatl J Jr (eds): CMV-Related Immunopathology. Monogr Virol. Basel, Karger, 1998, vol 21, pp 90-105.
3. Thomsen DR, Stenberg RM, Goins WF, Stiski MF: Promoter-regulatory region of the major immediate early gene of human cytomegalovirus. Proc Natl Acad Sci USA 1984;81:659-663.
4. Boldogh I, AbuBakar S, Albrecht T: Activation of proto-oncogenes: An immediate early event in human cytomegalovirus infection. Science 1991;247:561-564.
5. Kowalik TF, Wing B. Haskill JS, Azizkhan JC, Baldwin AJ, Huang ES: Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegaloviurs infection. Proc Natl Acad Sci USA 1993;90:1107-1111.
6. Mocarski ES, Abenes GB, Manning WC, Sambucetti LC, Cherrington JM: Molecular genetic analysis of cytomegalovirus gene regulation in growth, persistence and latency. Curr Top Microbiol Immunol 1990;154:47-74.
7. Sambucetti LC, Cherrington JM, Wilkinson GWG, Mocarski ES: NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J 1989;8:4251-4258.
8. Prösch S, Staak K, Stein J, Liebenthal C, Stamminger T, Volk HD, Krüger DH: Stimulation of the human cytomegalovirus IE enhancer/ promoter in HL-60 cells by TNF-alpha is mediated via induction of NF-κB. Virology 1995; 206:197-206.
9. Cherrington JM, Mocarski ES: Human cytomegalovirus ie1 transactivates the promoterenhancer via an 18-base-pair repeat clement. J Virol 1989;63:1435-1440.
10. Cherrington JM, Khoury EL, Mocarski ES: Human cytomegalovirus ie2 negatively regulates a gene expression via a short target sequence near the transcription start site. J Virol 1991;65:887-896.
11. Wu J, Jupp R, Stenberg RM, Nelson JA, Ghazal P: Site-specific inhibition of RNA polymerase II preinitiation complex assembly by human cytomegalovirus IE86 protein. J Virol 1993;67:7547-7555.
12. Lukae DM, Manuppello JR, Alwine JC: Transcriptional activation by the human cytomegalovirus proteins: Requirements for simple promoter structures and interactions with multiple components of the transcription complex. J Virol 1994;68:5184-5193.
13. von Willebrand E, Pettersson E, Ahonen J, Häyry P: CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986;42:364-367.
14. Pouteil Noble C, Ecochard R, Landrivon G, Donia Maged A, Tardy JC, Bosshard S, Colon S, Betuel H, Aymard M, Touraine JL: Cytomegalovirus infection - an etiologcial factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993;55: 851-857.
15. Lautenschlager I, Hockerstedt K, Jalanko H, Loginov R, Salmela K, Taskinen E, Ahonen J: Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997;25: 190-194.
16. Emanuel D, Cunningham I, Jules-Elysee K, Brockstcin JA, Kerman NA, Laver J, Stover D, White DA, Fels A, Polsky B, Castro-Malaspina H, Peppard JR, Bartus P, Hammerling U, O'Reilly RR: Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109:777-782.
17. Holland GN, Pepose JS, Pettit DH: Acquired immune deficiency syndrome: Ocular manifestations. Ophthalmology 1983;90:859-873.
18. Craigen JL, Grunds JE: Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 1996;62:1102-1108.
19. Grundy JE, Lawson KM, MacCormac LP, Fletcher JM, Yong KL: Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of CXC chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration. J Infect Dis 1998;177:1465-1467.
20. Scholz M, Blaheta RA, Cinatl J, Encke A, Doerr HW, Markus BH: Lymphocytes induce enhanced expression of HLA class I antigens on cytomegalovirus-infected syngeneic human endothelial cells. Hum Immunol 1995;44:136-144.
21. Scholz M, Hamann A, Blaheta RA, Auth MKH, Eneke A, Markus BH: Cytomegalovirus-and interferon-related effects on human endothelial cells: Cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interteron-γ. Human Immunol 1992;35:230-238.
22. Grundy JE, Downes KL: Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. Immunology 1993;78:405-412.
23. Span AHM, Mullers W, Miltenburg AMM, Bruggeman CA: Cytomegalovirus-induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers. Immunology 1991;72:355-360.
24. Tuder RM, Weinberg A, Panatjotoboulos N, Kalil J: Cytomegalovirus enhances PBMC binding and HLA class I expression on cultured endothelial cells. Transplant Proc 1991; 23:91.
25. Grundy JE, Pahal GS, Akbar AN: Increased adherence of CD2 peripheral blood lymphocytes to cytomegalovirus-infected fibroblasts is blocked by anti-LFA-3 antibody. Immunology 1993;78:413-420.
26. Blaheta R, Hailer N, Harder S, Scholz M, Bereiter-Hahn J, Markus BH: Up-and down regulation of lymphocyte infiltration through allogeneic endothelial cell monolayers. Tex Med 1994;6:53-59.
27. Michelson S, Dal Monte P, Zipeto D, Bodaghi B, Laurent L, Oberlin E, Arenzana-Scisdesos F, Virelizier J-L. Landini MP: Modulation of RANTES production by human cytomegalovirus infection of fibroblasts. J Virol 1997;71: 6495-6500.
28. Murayama T, Ohara Y, Obuchi M, Khahar KSA, Higashi H, Mukaida N, Matsushima K: Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line THP-1, through acting concurrently on AP-1 and NF-κB-binding sites of the interleukin-8 gene. J Virol 1997;71:5692-5695.
29. Craigen JL, Yong KL, Jordan JN, MacCormac LP, Westwick J, Akbar AN, Grundy JE: Human cytomegalovirus infection upregulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 1997;92:138-145.
30. Burns L, Pooley JC, Walsh DJ, Vercelloti GM, Weber ML, Kovacs A: Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins. Transplantation 1999;67:137-144.
31. Vossen RC, Persoons MC, Slobbe-van Drunen ME, Bruggeman CA, van Dam-Mieras MC: Intracellular thiol redox status affects rat cytomegalovirus infection of vascular cells. Virus Res 1997;48:173-183.
32. Scholz M, Cinatl J, Gross V, Vogel J-U, Blaheta RA, Freisleben H-J, Markus BH: Impact of oxidative stress on human cytomegalovirus replication and on cytokine-mediated stimulation of endothelial cells. Transplantation 1996;61: 1763-1770.
33. Cinatl J Jr, Kotchetkov R, Weimer E, Blaheta RA, Scholz M, Vogel J-U, Gümbel HO, Doerr HW: The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts. J Med Virol, in press.
34. Vogel J-U, Scholz M, Cinatl J Jr: Treatment of CMV diseases. Intervirology 1998;40:357-367.
35. Cinatl J Jr, Kotchetkov R, Scholz M, Cinatl J, Vogel J-U, Hernáiz-Driever P, Doerr HW: Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am J Pathol 1999;155:285-292.
36. Anderson KP, Fox MC, Driver VB, Martin MJ, Azad RF: Inhibition of human cytomegalovirus immediate early gene expression by an antisense oligonucleotide complementary to immediate early RNA. Antimicrob Agents Chemother 1999;40:2004-2011.
37. Azad RF, Driver VB, Tanaka K, Crooke RM, Anderson KP: Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993;37:1945-1954.
38. Marwick C: First 'antisense' drug will treat CMV retinitis. JAMA 1998;280:871.
39. Perry CM, Balfour JAB: Fomivirsen. Drugs 1999;57:375-380.
40. De Clereq E: Fomivirsen: A viewpoint. Drugs 1999;57:381.